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abies born with Pompe disease
require life-long treatment with
enzyme-replacement therapy (ERT).
Despite the human origin of the therapy,
recombinant human lysosomal acid α
glucosidase (GAA, rhGAA), ERT unfortunately leads to the development of high
titers of anti-rhGAA antibody, decreased
effectiveness of ERT, and a fatal outcome
for a significant number of children who
have Pompe disease. The severity of disease, anti-drug antibody (ADA) development, and the consequences thereof
are directly related to the degree of the
enzyme deficiency. Babies born with a
complete deficiency GAA are said to have
cross-reactive immunologic material
(CRIM)-negative Pompe disease and are
highly likely to develop GAA ADA. Less
frequently, GAA ADA develop in CRIMpositive individuals. Currently, GAAADA sero-positive babies are treated with
a combination of immunosuppressive
drugs to induce immunological tolerance to ERT, but the long-term effect of
these regimens is unknown. Alternative
approaches that might redirect the
immune response toward antigen-specific tolerance without immunosuppressive agents are needed. Methods leading
to the induction of antigen-specific regulatory T cells (Tregs), using peptides
such as Tregitopes (T regulatory cell
epitopes) are under consideration for
the future treatment of CRIM-negative
Pompe disease. Tregitopes are natural T
cell epitopes derived from immunoglobulin G (IgG) that cause the expansion
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and activation of regulatory T cells
(Treg). Teaching the immune system
to tolerate GAA by co-delivering GAA
with Tregitope peptides might dramatically improve the lives of CRIM-negative
babies and could be applied to other
enzyme replacement therapies to which
ADA have been induced.
Introduction
Pompe disease is a lysosomal storage
disorder caused by a deficiency in the
enzyme acid α-glucosidase (GAA). The
consequence of GAA deficiency is muscle
inflammation, disruption of muscle tissue,
and impaired function of heart and skeletal muscle. Although the advent of enzyme
replacement therapy (ERT) for Pompe
disease has had a dramatic impact on the
life expectancy of babies who are born
with this disorder, treatment advances are
still needed. Current therapy for Pompe
disease is based on early detection of the
genetic defect and infusions of the recombinant human enzyme acid α-glucosidase
(rhGAA) to prevent glycogen accumulation. Pompe-affected children who do
not express endogenous GAA (crossreactive immunologic material; CRIM)
and undergo myozyme treatment develop
high-titer anti-drug-antibodies (ADA)
because they are not immunologically
tolerant to GAA. ADA decrease GAA
enzyme uptake by muscle and/or inhibit
its activity. High ADA titers correlate with
poor outcomes, and even though ERT has
prolonged the life of Pompe disease babies,
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New approaches to enzyme replacement therapy for Pompe disease
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critical unmet medical with broad-reaching implications for other replacementprotein therapies that are also limited by
ADA (the Lysosomal Storage Disorders,
Hemophilia A and B, etc.).10-12
Natural Regulatory T cells,
Tregitopes and Tolerance
Induction
Autoreactive T cells with moderate T cell
receptor (TCR) affinity are known to
escape deletion in the thymus to circulate
in the periphery where they function as
‘natural’ regulatory T cells (nTreg) by suppressing immunity against self-antigens.13
Induced Tregs (iTregs), also known as
adaptive Tregs, are generated from circulating T effector cells; these cells perform
similar functions but have more plasticity.
It has become increasingly clear that both
nTregs and iTregs contribute to immune
regulation in the periphery and that their
presence, or absence, contributes to the
induction of tolerance and the development of autoimmunity and inflammation,
respectively.
One of the most fundamental questions about nTreg cells has been their
antigen-specificity. We surmised that
autologous proteins, such as immunoglobulin G (lgG), contain nTreg epitopes.
The presence of nTreg epitopes in lgG
might explain why immunoglobulins,
which undergo somatic hypermutation in
the periphery, do not elicit the expected
immune response against the new ‘foreign’ hypervariable sequences. After discovering highly promiscuous MHC class
II epitopes in the constant region of IgG,
we proposed that these epitopes were
nTreg epitopes (Tregitopes)14 that provide
inherent inhibitory signals to counter-balance any stimulatory signals that might
result from neo-epitopes expressed in Ab
hypervariable region.15 Two independent
publications support our hypothesis:
Ephrem and colleagues showed that intravenous immunoglobulin G (IVIg) induces
nTreg,6 and Anthony and Ravetch demonstrated the a linkage between immunoglobulin binding to surface receptors that
are associated with antigen-processing
pathways, and Treg induction by IVIg.16,17
We describe here our acquired knowledge
on the ability of Tregitope peptides to
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reduce T cell and T cell-dependent antibody responses, induce regulatory T cells,
and lessen disease scores in animal models
of inflammatory disease.18
Tregitopes have the following four
characteristics: (1) Their sequences are
highly conserved in IgG sequences; (2)
They bind to MHC class II promiscuously; (3) In response to Tregitopes, T
cells that exhibit a T regulatory phenotype (CD4 + CD25 + FoxP3 +) expand in
vitro and in vivo; and (4) Co-incubation
of Tregitopes with target autoantigens
such as pre-proinsulin inhibits effector T
cell (Teff) proliferation in vitro and suppresses the secretion of effector cytokines
(De Groot et al., unpublished and ref. 18).
We have more recently demonstrated
that APCs present Tregitopes to Treg,
engage feedback mechanisms promoting a
tolerogenic APC phenotype, induce Treg
expansion, and modulate antigen-specific
effector T cell responses (De Groot De
Groot et al., unpublished). Proportions
of APC expressing MHC II, CD80, and
CD86 are suppressed, consistent with
reported effects of IVIg19 and of the IgGderived peptide hCDR1.20 Moreover, we
have observed significant increases in proportions of IL-10-producing CD4 + CD25 +
FoxP3-expressing Treg in the presence
of Tregitopes. The basic mechanism of
Tregitope tolerance induction is currently
proposed to be as follows: (1) APC present
Tregitopes to nTreg, (2) nTreg are activated to proliferate and produce IL-10, (3)
nTreg provide tolerogenic feedback signals
to APC, modulating the APC phenotype, and (4) nTreg and tolerogenic APC
together suppress antigen-specific T cell
responses (De Groot et al., unpublished).
In Vivo Studies with Tregitopes
Modulation of T cell responses with
Tregitopes may contribute to the design
of new approaches for the treatment of
autoimmune and inflammatory diseases
via expansion of Tregs in vivo or ex vivo.
Experience with IVIg gives an example of
the therapeutic potential of this approach,
and evidence is accumulating that
Tregitopes provide beneficial immunomodulatory effects that in many respects
parallel IVIg. Within our collaborative
Tregitope network, we have performed a
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most CRIM-negative Pompe infants who
have complete GAA deficiency will eventually succumb to the disease if they are
not treated with tolerance-inducing drugs.
The development of experimental
immune tolerance regimens to inhibit
ADA against life-saving enzyme replacement therapy is an active area of investigation. Current approaches for mitigating
GAA-ADA are based on treatment with
methotrexate (MTX) to inhibit the proliferation of lymphocytes and Rituximab
(Rituxan) to deplete antibody (Ab)producing B cells.1-3 These approaches,
however, share significant limitations.
Namely, these treatments are not effective in eliminating long-lived plasma cells,
thus the timing of intervention in patients
experiencing an ADA response is critical.
Additional pharmacological agents that
suppress antibody production by longlived plasma cells might be of use, such as
a drug currently in use for plasma cell leukemia and multiple myeloma, Bortezomib
(Velcade).4 However, the long-term effects
of Rituximab and Bortezomib, that both
suppress the immune system systemically,
are as yet unknown. Finally, the association between the use of Rituximab and
development of certain infections has
been reported.5
In addition to these strategies aimed
at inhibiting proliferation or eliminating
lymphocyte subsets participating in the
ADA response are those aimed at modulating the immune system to become tolerant to the therapeutic protein. IVIG has
been shown to be associated with modulation of the regulatory T cell axis, including
induction of nTregs; 6 reduction of IL-17,7
and by enhancing the suppressive function
of Tregs.8 It has thus been applied with
much success in a number of autoimmune
diseases. A recent report describes the
clinical outcomes in two Pompe patients
who had received prolonged Rituximab
therapy for ADA who were also placed
on chronic IVIG in an effort to decrease
infectious complications. The addition of
IVIG may have provided an additional
immunomodulatory benefit in promoting
tolerance to the GAA therapy.9
Therapies that safely and permanently harness the immune system to
induce long-lasting and specific tolerance
in Pompe disease children will address a

Experimental model

Finding

Human disease
parallel

Current clinical
therapy

In vivo controls

Source

OVA-specific tolerance in
C57BL/6 mice

Suppression of T cell
proliferation; Suppression of
OVA-antibody titer

Enzyme
Replacement
Therapy

Immune
Tolerance
Induction

Influenza HA
(Negative CTR)
No effect;
IVIG CTR similar to
Tregitope

L. Cousens, A. De
Groot (EpiVax)

OVA-specific
tolerance in DO11.10
TCR Transgenics

Suppression of T cell
proliferation; induction of
antigen-specific Tregs

Enzyme
Replacement
Therapy

Immune
Tolerance
Induction

Influenza HA
peptide:
No effect

D.Scott,
Y. Su
(USUHS)

EAE prevention with
Tregitope

Reduction of EAE
symptoms; induction of
Tregs

OVA peptide
(Negative CTR)
No effect;
IVIG CTR similar to
Tregitope

S.Khoury;
W. Elyaman
(Brigham)

Albumin (Negative CTR)
No effect;
IVIG CTR similar to
Tregitope

B. Mazer,
A. Massoud
(McGill)

In C57Bl/6

Multiple
Sclerosis

Copaxone;
Interferon β
Tysabri; Campath

OVA Allergy Model;
Therapy with Tregitope
vs. IVIG

Reduction of allergic
response to OVA and airway
reactivity, increase in Treg
Induction

Allergy

Anti-histamines,
Immune
Tolerance
Induction

Tregitope in AAV;
TNBS-induced model of
inflammatory colitis

Reduction of clinical and
histological severity,
increased Treg infiltration in
the colon

Crohn’s Disease

Azathiaprine, AntiTNF Mabs, Steroids

Saline; No effect

V. Ferreira, S.
van der Marel
(UniQure)

Tregitope in AAV for
Gene Transfer

Suppressed CD8+-T cell
response to AAV epitope in
gene transfer model

Gene Transfer

Gene Transfer
Vectors currently induce CTL
response

Scrambled Tregitope
peptide
(Negative CTR)
No effect

F. Mingozzi
(CHOP)

Insulin Therapy

PPI peptides, TetTox
peptide
(Negative CTR)
No effect

L. Cousens,
A. De Groot
(EpiVax)

Tregitope in T1D (NOD
model)
with insulin peptides

Suppressed development of
diabetes; effect enhanced
when Tregitope co-delivered with insulin

number of studies to probe potential therapeutic applications of Tregitopes in mouse
models of MS (EAE), cardiac transplant,
diabetes (NOD), antigen-induced airway
hyper-responsiveness, and modulation of
viral vector immunogenicity in adenoassociated virus (AAV)-mediated gene
transfer.21 Together, the results obtained
in these models show that Tregitopes coadministered with proteins suppress antigen-specific T cell and antibody responses,
and induce expansion of functional
Tregs. Side-by-side in vivo comparisons
of Tregitope with IVIg have been performed in the autoimmune EAE model
[Khoury and Elyaman, personal communication] and antigen-induced allergic airway disease [Mazer and Massoud,
personal communication], demonstrating that IVIg effects can be replicated by
Tregitope administration. Adaptation or
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Type I Diabetes

incorporation of Tregitopes in drug design
may aid in the design of improved tolerance-inducing therapies, and safer, more
effective protein therapeutics.
Natural (n)Treg participate in central tolerance by controlling immune
responses to autologous proteins, and
in peripheral tolerance by stimulating
induced (i)Treg cells.22 Induction of iTreg
is associated with sustained tolerance to
transplants, allergens and autologous proteins.13,23,24 Tolerance can be induced with
non-depleting anti-CD4 antibodies25,26
and with AAV vector-mediated expression of antigens in the liver,27 including
rhGAA.28-30 IVIg, a source of Tregitopes,
induces tolerance in a number of different
settings such as solid organ transplant,31
eradication of FVIII and FIX inhibitory
antibodies in hemophilia patients,32-34 and
autoimmune diseases such as systemic
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lupus erythematosus (SLE35), idiopathic
thrombocytopenic purpura (ITP) and
chronic inflammatory demyelinating
polyneuropathy (CIDP).36-41 Of relevance to the goal of inducing tolerance
to rhGAA, IVIg has been used to reduce
ADA in Pompe patients undergoing
Myozyme treatment.9 See Table 1 for a list
of experiments that have been performed
with Tregitope, the human disease parallel, and a comment on current therapy for
that condition (highlighting the potential
role of Tregitope in the future therapy of
the condition).
How Could Tregitopes be Applied
to Pompe Disease Therapy?
We believe Tregitopes are natural, human
regulatory T cell epitopes (“Tregitopes”)
present in the Fc and Fab domains of IgG
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Table 1. Overview of Tregitope in vivo experiments and results

that may be responsible for tolerance to
idiotypic epitopes (Fig. 1). When incubated with peripheral blood mononuclear
cells (PBMCs) in vitro, Tregitopes specifically activate CD4 + T cells, increase
CD25/Foxp3 expression, and increase
expression of regulatory cytokines and chemokines.13 Administration of Tregitopes
with protein antigens in vivo inhibits T
cell proliferation and effector cytokine
expression. Tregitope effects are longlasting in a range of disease models (Table 1);
duration of effect extends at least 26 weeks
in NOD-T1D or 100 d in transplant (De
Groot et al., unpublished).42
As shown in Table 1 for T1D (last
row), co-administration of Tregitopes
with the antigen leads to even greater suppression of in vivo cytokine production,
T cell response, and antibody titers. The
combined efficacy of target antigen and
Tregitope, administered together, suggests
that Tregitopes induce antigen-specific
tolerance. This approach is deserving of
further investigation in Pompe disease
models.
Gene Transfer and Tregitopes
Gene transfer of GAA is under consideration as a therapy for Pompe disease.
Several studies in GAA-KO mice testing the AAV vector-driven expression of
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GAA show an initial robust expression of
GAA that is rapidly inactivated by ADA
responses.43-45 Low dose and liver-specific
expression of therapeutic enzymes may
lead to Treg-mediated tolerance,29 an effect
that may be enhanced by delivering GAA
fused to Tregitopes. EpiVax’ Tregitope collaborators Mingozzi and High (Children’s
Hospital of Philadelphia) have tested the
concept of Tregitope-induced tolerance
using AAV vectors in which Tregitopes are
fused to the expressed transgene.
To summarize their results: an AAV
vector expressing a protein antigen fused
to Tregitopes (or ‘scrambled’ Tregitopes as
a control) between which was engineered
a PACE/furin sequence that is susceptible to cleavage by intracellular proteases.
C57BL/6 mice received the Tregitope-fused
vector (or the scrambled control, n = 4 per
group). Four weeks later, mice were challenged with an adenoviral vector expressing
the antigen to trigger a strong CD8+ T cell
response against it.46 Ten days later, at the
peak of T cell responses triggered by the
adenoviral challenge, mice were sacrificed.
Tregitope co-delivery in this gene transfer
model effectively suppressed the development of effector (CD8 +) T cell responses
[Mingozzi and De Groot, unpublished].
Similarly, van der Marel et al. have
tested an AAV-5 vector carrying a human
Tregitope167-expressing cassette for its

Human Vaccines & Immunotherapeutics

Conclusions
Much progress has been made in the field
of enzyme-replacement therapy over the
past decade. New treatments are reaching
patients, and approaches that lead to the
reduction of ERT-ADA are under evaluation. Despite these significant advances,
the long-term effects of current immune
tolerance induction regimens have yet to be
defined. Proof-of-principle for Tregitopes
in treating ADA in the context of Pompe
disease would have an immediate impact
on the field of enzyme replacement therapy and could accelerate adaptation of
Tregitope therapy in the treatment of
these children. Tregitopes merit consideration even if they only reduce dependence
on immunosuppressive drugs, however
ongoing studies appear to indicate that
Tregitopes elicit antigen-specific tolerance, augmenting the potential benefits of
this approach in mitigating ADA. Thus,
further proof-of-principle studies with
Tregitopes are likely to have a far-reaching
impact on the clinical development of biologic therapies, including enzyme replacement therapy for Pompe disease.
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Figure 1. Hypothesized Tregitope mechanism of action. Treg epitopes (Tregitopes) present in
Fc and Fab domain of IgG drive tolerance to neo-epitopes pre-sent in the Fab hypervariable
domains. EpiVax discovered conserved T -cell epitopes in IgG that engage natural Treg. We hypothesize that Tregitopes (dark blue) activate Treg that lead to bystander suppression of effector T
cells that recognize effector epitopes (red) and, depending on the context, induction of antigenspecific Tregs (aTregs) to these epitopes.

ability to reduce the development of
inflammation in the TNBS model of
colitis [van der Marel, personal communication]. This reduction in inflammation was associated with an increase in the
presence of Tregs in the intestinal mucosa,
lamina propria and the thymus of AAV5Tregitope167-treated mice. Additionally,
expression of both Foxp3 and GARP were
increased in the thymic CD4 + T lymphocyte population in mice pre-treated
with AAV5-Tregitope167 but not in mice
treated with saline alone, suggesting that
Tregitope treatment increased activation
of regulatory T-cells.47-51 The presence of
higher numbers of activated regulatory T
cells in the AAV5-Tregitope-treated mice
corresponded with the prevention of fulminant intestinal inflammation in vivo, in
this TNBS model of inflammatory bowel
disease.
These two studies demonstrate that
AAV vector-mediated co-delivery of
Tregitopes with the enzyme replacement
therapies could represent an alternative
Tregitope-based approach to induce specific tolerance to GAA.

A.S.DG. and W.M. are senior officers and
majority shareholders at EpiVax, Inc., a
privately owned vaccine design company
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senior scientist at EpiVax, Inc.
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